Signaling Pathway
Evunzekibart (ATOR-1017) is a 4-1BB agonist that functions conditionally through Fc-?? receptor engagement, classified as an IgG4-type antibody. This biologic is designed to activate immune responses against cancer cells either as a standalone treatment or in synergy with anti-PD1 therapies, enhancing its potential for anticancer efficacy.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Evunzekibart (ATOR-1017) is a 4-1BB agonist that functions conditionally through Fc-?? receptor engagement, classified as an IgG4-type antibody. This biologic is designed to activate immune responses against cancer cells either as a standalone treatment or in synergy with anti-PD1 therapies, enhancing its potential for anticancer efficacy. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
